B and BIOA-B Related Headlines
Go Back- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
- BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
B and BIOA-B Related Press Releases
Go Back- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
- BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
